Biogen Reports Quarterly Revenues of $3.1 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St futures drop as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- Oil gains over 3% as US-Iran peace talks in stalemate
- Stock action shows confidence in central banks: BofA’s Hartnett
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Biogen (BIIB) PT Lowered to $311 at RBC Capital
April 25, 2018 7:43 AM EDTRBC Capital lowered its price target on Biogen (NASDAQ: BIIB) to $311.00 (from $316.00) while maintaining a Sector Perform rating.
Analyst Brian Abrahams said Q1 softness stems from Spinraza and seasonality.
... MoreBiogen (BIIB) PT Lowered to $375 at Oppenheimer
April 25, 2018 7:15 AM EDTOppenheimer lowered its price target on Biogen (NASDAQ: BIIB) to $375.00 (from $400.00) while maintaining a Outperform rating.
Analyst Jay Olson commented, "A solid 1Q update addressed investor concerns on multiple fronts with decent financial results featuring an EPS beat of $6.05 vs $5.93E consensus and... More
Piper Jaffray Remains Bullish on Biogen (BIIB) Following 1Q
April 24, 2018 8:48 AM EDTPiper Jaffray reiterated an Overweight rating and $407.00 price target on Biogen (NASDAQ: BIIB) following the company's 1Q earnings report. BIIB posted total revenue of $3,131M, missing consensus $3,152M but beating Piper Jaffray's $3,080M estimate. Non-GAAP EPS of $6.05 easily beat consensus $5.93.
BIIB's anti-CD20... More
